EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen–Silica Nanoparticle Composites

Silvia Calvo-Serrano, Esther Matamoros, Jose Antonio Céspedes iD, Rubén Fernández-Santamaría iD, Violeta Gil-Ocaña, Ezequiel Perez-Inestrosa iD, Cecilia Frecha, Maria I Montañez iD, Yolanda Vida, Cristobalina Mayorga, Maria J Torres

Pharmaceutics · 03.08.2024 · 16 (8) · 1039

DOI: 10.3390/pharmaceutics16081039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 03.08.2024. Verfasst von Silvia Calvo-Serrano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de A…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the Spanish Ministerio de Ciencia e Innovación (Proyectos de I+D+I «Programación Conjunta Internacional», EuroNanoMed 2019 (PCI2019-…, Spanish Ministerio de Ciencia e Innovación (Proyectos de I+D+I «Programación Conjunta Internacional», EuroNanoMed 2019, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vitro cell activation through specific IgE bound to high-affinity receptors on the basophil surface is a widely used strategy for the evaluation of IgE-mediated immediate hypersensitivity reactions to betalactams. Cellular activation requires drug conjugation to a protein to form a large enough structure displaying a certain distance between haptens to allow the cross-linking of two IgE antibodies bound to the basophil’s surface, triggering their degranulation. However, no information about the size and composition of these conjugates is available. Routine in vitro diagnosis using the basophil activation test uses free amoxicillin, which is assumed to conjugate to a carrier present in blood. To standardize the methodology, we propose the use of well-controlled and defined nanomaterials functionalized with amoxicilloyl. Silica nanoparticles decorated with PAMAM–dendrimer–amoxicilloyl conjugates (NpDeAXO) of different sizes and amoxicilloyl densities (50–300 µmol amoxicilloyl/gram nanoparticle) have been prepared and chemically characterized. Two methods of synthesis were performed to ensure reproducibility and stability. Their functional effect on basophils was measured using an in-house basophil activation test (BAT) that determines CD63+ or CD203chigh activation markers. It was observed that NpDeAXO nanocomposites are not only able to specifically activate basophils but also do so in a more effective way than free amoxicillin, pointing to a translational potential diagnosis.

Schlagwörter

Stichwörter der Autor:innen

PAMAM dendrimersbasophil activation testdendrimeric antigensdrug allergy diagnosissilica nanoparticles

Autor:innen und Institutionen

  • Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.
  • RICORS Red de Enfermedades Inflamatorias (REI), 28029 Madrid, Spain.
  • Departamento de Medicina y Dermatología, Universidad de Málaga, 29071 Málaga, Spain.
  • Departamento de Química Orgánica, Universidad de Málaga, Campus Teatinos s/n, 29071 Málaga, Spain.
  • Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.
  • Allergy Unit, Hospital Regional Universitario de Málaga-HRUM, 29010 Málaga, Spain.

ORCID-Profile: Jose Antonio Céspedes, Rubén Fernández-Santamaría, Ezequiel Perez-Inestrosa, Maria I Montañez

Förderung

  • This work was supported by the Spanish Ministerio de Ciencia e Innovación (Proyectos de I+D+I «Programación Conjunta Internacional», EuroNanoMed 2019 (PCI2019-…
  • Spanish Ministerio de Ciencia e Innovación (Proyectos de I+D+I «Programación Conjunta Internacional», EuroNanoMed 2019
  • Ministerio de Ciencia e Innovación
  • Instituto de Salud Carlos III (ISCIII)
  • RICORS Red de Enfermedades Inflamatorias
  • Junta de Andalucía
  • Andalusian Regional Ministry Health
  • European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie

Zitieren

APA

Calvo-Serrano, S., Matamoros, E., Céspedes, J. A., Fernández-Santamaría, R., Gil-Ocaña, V., Perez-Inestrosa, E., Frecha, C., Montañez, M. I., Vida, Y., Mayorga, C., & Torres, M. J. (2024). New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen–Silica Nanoparticle Composites. Pharmaceutics, 16(8), 1039. https://doi.org/10.3390/pharmaceutics16081039

Vancouver

Calvo-Serrano S, Matamoros E, Céspedes JA, Fernández-Santamaría R, Gil-Ocaña V, Perez-Inestrosa E, et al. New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen–Silica Nanoparticle Composites. Pharmaceutics. 2024;16(8):1039. doi:10.3390/pharmaceutics16081039

BibTeX
@article{CalvoSerrano2024,
  author = {Calvo-Serrano, Silvia and Matamoros, Esther and Céspedes, Jose Antonio and Fernández-Santamaría, Rubén and Gil-Ocaña, Violeta and Perez-Inestrosa, Ezequiel and Frecha, Cecilia and Montañez, Maria I and Vida, Yolanda and Mayorga, Cristobalina and Torres, Maria J},
  title = {New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen–Silica Nanoparticle Composites},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {8},
  pages = {1039},
  doi = {10.3390/pharmaceutics16081039}
}
Kostenlos starten →